Investing in proven biosimilars in ophthalmology and oncology
Valorum is interested in assets with clear and defined paths to approval and high returns on investment. Our pipeline aims to provide cost-effective and timely solutions to patients’ unmet needs.
Pipeline
preclinical
phase iphase iiiFDA/EMA Approval
AHZANTIVE©
Ophthalmology
ARMLUPEG©
Oncology
VA-2*
Ophthalmology
| Indications | Phase/Status | |
|---|---|---|
|
AHZANTIVE© Ophthalmology |
|
FDA/EMA Approval |
| ARMLUPEG© Oncology |
|
FDA/EMA Approval |
|
VA-2* Ophthalmology |
|
FDA/EMA Approval |
* EMA Approved